Novartis - Stock

Novartis Revenue 2024

Novartis Revenue

50.02 B USD

Ticker

NOVN.SW

ISIN

CH0012005267

WKN

904278

In 2024, Novartis's sales reached 50.02 B USD, a 7.19% difference from the 46.66 B USD sales recorded in the previous year.

The Novartis Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e53.6264,61
2028e54.1164,02
2027e52.6365,82
2026e52.7865,63
2025e52.0766,53
2024e50.0269,26
202346.6674,24
202243.3874,15
202143.9774,10
202049.971,14
201948.6271,35
201846.0270,54
201743.3669,06
201649.3964,89
201550.3665,99
201453.6367,66
201358.8366,67
201257.5667,42
201159.3868,03
201051.5671,90
200945.173,00
200842.5873,14
200738.9571,67
200636.7571,97
200532.5372,74
200428.2576,55

Novartis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Novartis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novartis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novartis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Novartis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Novartis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Novartis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novartis’s growth potential.

Novartis Revenue, Profit, and EBIT History

DateNovartis RevenueNovartis EBITNovartis Net Income
2029e53.62 B undefined0 undefined17.55 B undefined
2028e54.11 B undefined21.98 B undefined18.39 B undefined
2027e52.63 B undefined20.98 B undefined17.13 B undefined
2026e52.78 B undefined18.81 B undefined16.59 B undefined
2025e52.07 B undefined18.3 B undefined15.92 B undefined
2024e50.02 B undefined17.03 B undefined14.51 B undefined
202346.66 B undefined12.64 B undefined14.85 B undefined
202243.38 B undefined10.21 B undefined6.96 B undefined
202143.97 B undefined10.96 B undefined24.02 B undefined
202049.9 B undefined12.32 B undefined8.07 B undefined
201948.62 B undefined11.33 B undefined11.73 B undefined
201846.02 B undefined9.89 B undefined12.61 B undefined
201743.36 B undefined9.1 B undefined7.7 B undefined
201649.39 B undefined9.19 B undefined6.71 B undefined
201550.36 B undefined10 B undefined17.78 B undefined
201453.63 B undefined11.09 B undefined10.21 B undefined
201358.83 B undefined10.91 B undefined9.18 B undefined
201257.56 B undefined11.51 B undefined9.51 B undefined
201159.38 B undefined11 B undefined9.11 B undefined
201051.56 B undefined11.53 B undefined9.79 B undefined
200945.1 B undefined9.98 B undefined8.4 B undefined
200842.58 B undefined8.96 B undefined8.2 B undefined
200738.95 B undefined6.78 B undefined11.95 B undefined
200636.75 B undefined7.95 B undefined7.18 B undefined
200532.53 B undefined6.91 B undefined6.13 B undefined
200428.25 B undefined6.54 B undefined5.77 B undefined

Novartis stock margins

The Novartis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novartis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novartis.
  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Novartis's sales revenue. A higher gross margin percentage indicates that the Novartis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Novartis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Novartis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novartis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novartis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novartis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Novartis Margin History

Novartis Gross marginNovartis Profit marginNovartis EBIT marginNovartis Profit margin
2029e74.24 %0 %32.74 %
2028e74.24 %40.62 %33.98 %
2027e74.24 %39.87 %32.55 %
2026e74.24 %35.65 %31.44 %
2025e74.24 %35.14 %30.57 %
2024e74.24 %34.05 %29.02 %
202374.24 %27.09 %31.83 %
202274.15 %23.53 %16.03 %
202174.1 %24.93 %54.63 %
202071.14 %24.69 %16.18 %
201971.35 %23.31 %24.13 %
201870.54 %21.49 %27.41 %
201769.06 %20.98 %17.76 %
201664.89 %18.6 %13.59 %
201565.99 %19.86 %35.31 %
201467.66 %20.68 %19.04 %
201366.67 %18.54 %15.6 %
201267.42 %20 %16.51 %
201168.03 %18.52 %15.35 %
201071.9 %22.35 %18.99 %
200973 %22.13 %18.62 %
200873.14 %21.05 %19.24 %
200771.67 %17.41 %30.67 %
200671.97 %21.63 %19.52 %
200572.74 %21.23 %18.85 %
200476.55 %23.15 %20.42 %

Novartis Aktienanalyse

What does Novartis do?

Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Novartis's Sales Figures

The sales figures of Novartis originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Novartis’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Novartis's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Novartis’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Novartis Stock

How much revenue did Novartis generate this year?

Novartis has achieved a revenue of 50.02 B USD this year.

How much was the turnover of the company Novartis compared to the previous year?

The revenue of Novartis has increased by 7.19% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Novartis?

The revenue of Novartis is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Novartis measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Novartis so important for investors?

The revenue of Novartis is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Novartis pay?

Over the past 12 months, Novartis paid a dividend of 3.2 USD . This corresponds to a dividend yield of about 3.02 %. For the coming 12 months, Novartis is expected to pay a dividend of 3.28 USD.

What is the dividend yield of Novartis?

The current dividend yield of Novartis is 3.02 %.

When does Novartis pay dividends?

Novartis pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of Novartis?

Novartis paid dividends every year for the past 26 years.

What is the dividend of Novartis?

For the upcoming 12 months, dividends amounting to 3.28 USD are expected. This corresponds to a dividend yield of 3.1 %.

In which sector is Novartis located?

Novartis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novartis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novartis from 3/11/2024 amounting to 3.3 USD, you needed to have the stock in your portfolio before the ex-date on 3/7/2024.

When did Novartis pay the last dividend?

The last dividend was paid out on 3/11/2024.

What was the dividend of Novartis in the year 2023?

In the year 2023, Novartis distributed 3.1 USD as dividends.

In which currency does Novartis pay out the dividend?

The dividends of Novartis are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novartis stock can be added to a savings plan with the following providers: ING

Andere Kennzahlen von Novartis

Our stock analysis for Novartis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novartis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.